Structure-based design used as tool for engineering deimmunized biotherapeutics

In the first experimental use of algorithms that employ structure-based molecular modeling to optimize deimmunized drug candidates, researchers complement their prior sequence-based deimmunizing algorithms and expand the tool kit of protein engineering technologies to use in next generation drug development.